COLUMBIA, Maryland and BILLERICA, Massachusetts, February 12 /PRNewswire/ --
- Pay-Per-Patient Pricing Available to Reduce Start-Up Barriers for Cancer Centers
Nucletron, a knowledge-based leader in radiation oncology, and Advanced Radiation Therapy (ART) announced today an exclusive global, strategic partnership to offer the AccuBoost(R) system with the microSelectron(R) high- dose rate (HDR) brachytherapy afterloader treatment delivery solution for the treatment of breast cancer. The partnership will enable clinicians all over the world to deliver boost brachytherapy as part of the whole breast irradiation procedure, providing a superior treatment option with the ultimate goal of improving clinical outcome.
The partnership offers radiation oncology centers the opportunity to implement ART's innovative technology in image-guided HDR breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron's treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support. ART's expansion of AccuBoost technology through its global partnership with Nucletron will further reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.
"We are thrilled to partner with ART and expand the availability and
utilization of HDR brachytherapy globally," said Jos Lamers, chief executive
officer for Nucletron. "Using Nucletron's microSelectron Digital afterloader
to deliver AccuBoost technology further reduces the financial, operational,
and clinical barriers many cancer centers encounter in providing
brachytherapy to their patients. In conjunction with this announcement,
Nucletron is offering a pay-per-patient pricing model for centers bundling
the AccuBoost treatment option with their new HDR brachyt
|SOURCE Nucletron B V|
Copyright©2009 PR Newswire.
All rights reserved